Clinical Trial

Immune Profiling for Cancer Immunotherapy Response

Recruiting
View on ClinicalTrials.gov →
Summary
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-30; most recent amendment 2025-12-09.
Trial Details
NCT Number NCT06116032
Lead Sponsor Dartmouth-Hitchcock Medical Center
Conditions Cancer, Tumor, Solid, Hematologic Malignancy, Blood Cancer
Enrollment 1,500 participants
Start Date 2022-10-03
Primary Completion 2027-01-01 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-16